Medicare has agreed to provide broader coverage once Leqembi receives full FDA approval.
Even if the FDA grants full approval of the Alzheimer’s treatment Leqembi, the rollout will take years.
The FDA’s decision comes after clinical trial results indicated that lecanemab slows cognitive decline somewhat in people with mild impairment from Alzheimer’s.
){kind=link}
){kind=link}
){kind=link}
){kind=link}